Aa
Replicor - independent source
Potential Cure for Patients With Chronic HBeAg-negative
REP compounds are nucleic acid polymers (NAPs) that block the release of subviral particles (hepatitis B surface antigen [HBsAg]) from HBV-infected hepatocytes, leading to efficient clearance of HBsAg from the blood. It was recently documented that the NAP REP 2139 was capable of reducing serum HBsAg levels during chronic HBV infection, improving the efficacy of immunotherapy and facilitating establishment of functional control off treatment.
Bazinet and colleagues[17] conducted a randomized, controlled trial assessing the safety and efficacy of REP 2139 and a REP 2139 derivative with improved clearance (REP 2165) infused once a week in combination with tenofovir disoproxil fumarate and pegylated interferon alpha-2a in treatment-naive patients with chronic HBeAg-negative infection. This triple-combination therapy was well tolerated in all patients, and no infusion reactions were observed with either NAP.
The investigators reported that after 12 weeks of NAP exposure, there was a > 90% decrease in circulating HBsAg levels, along with an increase in serum anti-HBs levels. NAP-mediated HBsAg reductions were accompanied by otherwise asymptomatic rises in ALT and AST levels, indicating a restored immune response in the liver. These preliminary data demonstrate the tolerability and efficacy of REP 2139 and REP 2165 when used in combination with pegylated interferon alpha-2a and tenofovir disoproxil fumarate in patients with HBeAg-negative chronic HBV infection. NAP-mediated HBsAg clearance improves the efficacy of pegylated interferon alpha-2a in this patient population.
REP compounds are nucleic acid polymers (NAPs) that block the release of subviral particles (hepatitis B surface antigen [HBsAg]) from HBV-infected hepatocytes, leading to efficient clearance of HBsAg from the blood. It was recently documented that the NAP REP 2139 was capable of reducing serum HBsAg levels during chronic HBV infection, improving the efficacy of immunotherapy and facilitating establishment of functional control off treatment.
Bazinet and colleagues[17] conducted a randomized, controlled trial assessing the safety and efficacy of REP 2139 and a REP 2139 derivative with improved clearance (REP 2165) infused once a week in combination with tenofovir disoproxil fumarate and pegylated interferon alpha-2a in treatment-naive patients with chronic HBeAg-negative infection. This triple-combination therapy was well tolerated in all patients, and no infusion reactions were observed with either NAP.
The investigators reported that after 12 weeks of NAP exposure, there was a > 90% decrease in circulating HBsAg levels, along with an increase in serum anti-HBs levels. NAP-mediated HBsAg reductions were accompanied by otherwise asymptomatic rises in ALT and AST levels, indicating a restored immune response in the liver. These preliminary data demonstrate the tolerability and efficacy of REP 2139 and REP 2165 when used in combination with pegylated interferon alpha-2a and tenofovir disoproxil fumarate in patients with HBeAg-negative chronic HBV infection. NAP-mediated HBsAg clearance improves the efficacy of pegylated interferon alpha-2a in this patient population.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
